Literature DB >> 18703007

B cells and multiple sclerosis.

Diego Franciotta1, Marco Salvetti, Francesco Lolli, Barbara Serafini, Francesca Aloisi.   

Abstract

Clonal expansion of B cells and the production of oligoclonal IgG in the brain and cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS) have long been interpreted as circumstantial evidence of the immune-mediated pathogenesis of the disease and suggest a possible infectious cause. Extensive work on intrathecally produced antibodies has not yet clarified whether they are pathogenetically relevant. Irrespective of antibody specificity, however, the processes of antibody synthesis in the CNS of patients with MS are becoming increasingly clear. Likewise, targeting B cells might be therapeutically relevant in MS and other autoimmune diseases that are deemed to be driven predominantly by T cells. Accumulating evidence indicates that in MS, similar to rheumatoid arthritis, B cells aggregate into lymphoid-like structures in the target organ. The process of aggregation is mediated through the expression of lymphoid-homing chemokines. In the brain of a patient with MS, ectopic B-cell follicles preferentially adjoin the pial membrane within the subarachnoid space. Recent findings indicate that substantial numbers of B cells that are infected with Epstein-Barr virus (EBV) accumulate in these intrameningeal follicles and in white matter lesions and are probably the target of a cytotoxic immune response. These findings, which await confirmation, could be an explanation for the continuous B-cell and T-cell activation in MS, but leave open concerns about the possible pathogenicity of autoantibodies. Going beyond the antimyelin-antibody dogma, the above data warrant further work on various B-cell-related mechanisms, including investigation of B-cell effector and regulatory functions, definition of the consistency of CNS colonisation by Epstein-Barr virus-infected B cells, and understanding of the mechanisms that underlie the formation and persistence of tertiary lymphoid tissues in patients with MS and other chronic autoimmune diseases (ectopic follicle syndromes). This work will stimulate new and unconventional ways of reasoning about MS pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18703007     DOI: 10.1016/S1474-4422(08)70192-3

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  85 in total

1.  Intrathecal methotrexate treatment in multiple sclerosis.

Authors:  Saud A Sadiq; Elena V Simon; Lauren M Puccio
Journal:  J Neurol       Date:  2010-06-10       Impact factor: 4.849

Review 2.  Development of anti-CD20 therapy for multiple sclerosis.

Authors:  Beatrix Bartok; Gregg J Silverman
Journal:  Exp Cell Res       Date:  2011-04-12       Impact factor: 3.905

3.  Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study).

Authors:  O Fernández; V Fernández; T Arbizu; G Izquierdo; I Bosca; R Arroyo; J A García Merino; E de Ramón
Journal:  J Neurol       Date:  2010-04-10       Impact factor: 4.849

4.  Negative association of Epstein-Barr virus or herpes simplex virus-1 with tumefactive central nervous system inflammatory demyelinating disease.

Authors:  Takao Kiriyama; Hiroshi Kataoka; Takahiko Kasai; Akitaka Nonomura; Satoshi Ueno
Journal:  J Neurovirol       Date:  2010-11-11       Impact factor: 2.643

Review 5.  [Stem cell therapy in multiple sclerosis: a clinical update].

Authors:  S Schippling; R Martin
Journal:  Z Rheumatol       Date:  2009-05       Impact factor: 1.372

6.  C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE.

Authors:  Andrea Reboldi; Caroline Coisne; Dirk Baumjohann; Federica Benvenuto; Denise Bottinelli; Sergio Lira; Antonio Uccelli; Antonio Lanzavecchia; Britta Engelhardt; Federica Sallusto
Journal:  Nat Immunol       Date:  2009-03-22       Impact factor: 25.606

Review 7.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

Authors:  Ankit Saxena; Sam Khosraviani; Sanjeev Noel; Divya Mohan; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cytokine       Date:  2014-12-04       Impact factor: 3.861

8.  Decreased Dicer expression is linked to increased expression of co-stimulatory molecule CD80 on B cells in multiple sclerosis.

Authors:  Latt Latt Aung; Konstantin E Balashov
Journal:  Mult Scler       Date:  2014-12-05       Impact factor: 6.312

9.  Recruitment and retention of B cells in the central nervous system in response to alphavirus encephalomyelitis.

Authors:  Talibah U Metcalf; Victoria K Baxter; Voraphoj Nilaratanakul; Diane E Griffin
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

Review 10.  [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

Authors:  H-P Hartung
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.